REGN:Regeneron Pharmaceuticals Inc Snapshot | Charting | News | Options
$890.68   0.00%  $0.00 NASDAQ 4:00p ET
April 7 '24 		Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patien... GlobeNewswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
     GlobeNewswire
    Full Story →

    Headline News
    Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
    4:05p ET April 1 '24 GlobeNewswire
    SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
    9:00a ET March 27 '24 BusinessWire
    Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
    1:20p ET March 22 '24 GlobeNewswire
    More News →
    Day  0.00%Week  0.68%Month  7.83%More Charting →
    April 25 '24. Markets Closed.
    Last $890.68
    Day change   0.00%$0.00
    Open $911.09
    Gap at open $20.41
    Previous close $890.68
    Trading volume 576,565
    10 Day avg vol. 500,710
    Shares out. 109.8Mil
    Market cap. $97.8Bil
    Trading activity Above Avg.
    Previous data from yesterday, April 24 '24.

    Historical Price Performance
    3 month   5.25% 
    6 month   14.90% 
    1 year   12.42% 
    2 year   32.24% 

    Earnings
    Previous 12m $34.76
    Next 12m Estimate $45.03
    P/E ratio 25.6x
    Revenue 13,117Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2024 All rights reserved.